Intrinsic Imaging Awarded Phase II Trial for Metastatic Pancreatic Cancer

Bolton, MA / San Antonio, TX — June 20, 2012 — Intrinsic Imaging, an ISO 9001 certified and GAMP 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials, announces today that it was recently awarded a Phase II efficacy trial for Metastatic Pancreatic Cancer.

This clinical research study utilizes a novel investigational biologic treatment for patients with any stage of metastatic pancreatic adenocarcinoma or advanced colorectal cancer that no longer responds to standard therapies. During this trial, Intrinsic Imaging will study treatment response of the patient’s cancer by evaluating images using Response Evaluation Criteria in Solid Tumors (RECIST). Intrinsic Imaging will also provide qualitative and quantitative assessments of metabolic tumor response using PET Response Criteria in Solid Tumors (PERCIST).

“The award of this critical Phase II trial to Intrinsic Imaging is a testament of the continued trust and respect we have earned from Sponsors as a preferred imaging core lab for clinical trials.” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “We are very pleased to contribute our therapeutic expertise towards the development of this novel ground breaking treatment for Metastatic Pancreatic Cancer.”

Intrinsic Imaging’s team of more than sixty board-certified diagnostic radiologists have sub-specialization in all therapeutic areas including, but not limited to, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, Medical Device, and Oncology. The Oncology team consists of 12 oncology trained board-certified radiologists and 8 board-certified interventional oncology radiologists who have in-depth experience in pancreatic, colorectal, breast, lung, ovarian and prostate cancer, among others.